Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis

@article{Sandberg2014OverweightDT,
  title={Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis},
  author={Maria E. C. Sandberg and Camilla Bengtsson and Henrik K{\"a}llberg and Annmarie Wesley and Lars Klareskog and Lars Alfredsson and Saedis Saevarsdottir},
  journal={Annals of the Rheumatic Diseases},
  year={2014},
  volume={73},
  pages={2029 - 2033}
}
Aim To investigate whether overweight/obesity at diagnosis affects the chances of decrease in disease activity and pain in early rheumatoid arthritis (RA). Method We investigated incident RA cases from the population-based Epidemiological Investigation of risk factors for Rheumatoid Arthritis (EIRA) study (2006–2009, N=495) with clinical follow-up in the Swedish Rheumatology Quality Register. At diagnosis, 93% received disease-modifying antirheumatic drugs (DMARDs) (86% methotrexate). The odds… 

Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial

In this early RA trial reflecting today’s standard treatment, obesity, in addition to sex, smoking and functional impairment strongly lowered the chance of attaining good clinical outcomes, including remission, today's treatment goal.

Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis

Patients with RA and obesity have lower rates of DAS28 remission but similar rates of low MRI activity compared with patients without obesity, suggesting that obesity and its associated comorbidities can bias clinical disease activity measures.

No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study

BMI is not a predictive factor of clinical response to bDMARDs in patients with RA, and Logistic regression analysis showed no relationship of BMI with EULAR clinical responses.

Obesity Associated With Active, but Preserved Joints in Rheumatoid Arthritis: Results From our National Registry.

It is indicated that obesity is more common in patients with RA than the general population and associations with disease outcomes are associated with high BMI in this National RA-Registry.

Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis

It is suggested that obesity and overweight reduce the chances to achieve minimal disease activity (MDA) in patients with rheumatic diseases receiving treatment with traditional or biologic disease-modifying antirheumatic drugs.

Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs

Obesity was negatively associated with RA disease remission regardless of RA therapy, suggesting that baseline BMI should be considered as a stratification factor in future RA trials.

The association between increased body mass index and response to conventional synthetic DMARD treatment in rheumatoid arthritis: Results from the METEOR database.

Obese patients on monotherapy were significantly less likely to achieve good EULAR response or DAS28 remission at 6 months and more likely to be treated with combination csDMARDs, compared with normal BMI, similar response rates were observed in early RA but increased BMI was associated with reduced response in established RA.

The Influence of Overweight and Obesity on Treatment Response in Juvenile Idiopathic Arthritis

A significant correlation between obesity and a greater involvement of the joints of the lower limbs at baseline was demonstrated and the data suggest that obesity could negatively influence the course of the disease as well as treatment response.

Obesity and Remission Rates in Japanese Patients With Rheumatoid Arthritis Requiring Anti-Tumor Necrosis Factor Alpha Therapy

It is found that there is no statistically significant association between obesity and poor response to anti-TNFα therapy in Japanese patients with RA.

Comparison of Psoriatic Arthritis and Rheumatoid Arthritis Patients across Body Mass Index Categories in Switzerland

Obese PsA and RA patients presented worse disease activity and poorer QoL than those with normal weight, while obese RA patients had significantly higher erythrocyte sedimentation rate and tender joint counts, as well as lower seropositive prevalence.
...

References

SHOWING 1-10 OF 23 REFERENCES

Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index.

BMI provides a risk estimate of joint damage in RA patients and the possible role of adipose tissue is investigated.

Smoking and overweight determine the likelihood of developing rheumatoid arthritis

This is the first prospective study showing that smoking and overweight increase the risk of development of arthritis in a cohort of autoantibody-positive individuals at risk for developing RA.

Evidence for the benefit of aerobic and strengthening exercise in rheumatoid arthritis.

The evidence for the benefit of aerobic and strengthening exercise in RA is investigated to provide scientific support that various forms of exercise are both safe and beneficial.

Body mass index and clinical response to infliximab in rheumatoid arthritis.

The notion that adipose tissue may be involved in the pathophysiology of RA and could have implications for other immune-mediated inflammatory conditions treated with TNF antagonists is supported.

Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis.

Among patients with RA, low BMI is associated with a significantly increased risk of cardiovascular death.

Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy.

Pain levels are almost constant over RA duration, and are increased in women, ethnic minorities, smokers, and those with less education.

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.

Adherence to these recommendations will provide the readership of clinical trials with more details of important outcomes, while the higher level of homogeneity may facilitate the comparison of outcomes across different trials and pooling of trial results, such as in meta-analyses.

Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases

Smokers of both sexes have an increased risk of developing seropositive, but not seronegative, RA, which occurs after a long duration, but merely a moderate intensity, of smoking and may remain for several years after smoking cessation.

Obesity and reduction of the response rate to anti–tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine

Whether obesity represents a risk factor for a poor remission rate in RA patients requiring anti–tumor necrosis factor α (anti‐TNFα) therapy for progressive and active disease despite treatment with methotrexate or other disease‐modifying antirheumatic drugs is investigated.

Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: A long‐term followup from disease onset

To determine the association of obesity, defined as a body mass index (BMI) ≥30 or ≥28 kg/m2 or by waist circumference (WC), with disease activity and severity, as well as its relationship to